Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study

Objectives To assess whether a double therapy combination consisting of diuretics, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers with addition of non-steroidal anti-inflammatory drugs (NSAIDs) and the triple therapy combination of two of the aforementioned antihypertensive drugs to which NSAIDs are added are associated with an increased risk of acute kidney injury. Design Retrospective cohort study using nested case-control analysis. Setting General practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database. Participants A cohort of 487 372 users of antihypertensive drugs. Main outcome measures Rate ratios with 95% confidence intervals of acute kidney injury associated with current use of double and triple therapy combinations of antihypertensive drugs with NSAIDs. Results During a mean follow-up of 5.9 (SD 3.4) years, 2215 cases of acute kidney injury were identified (incidence rate 7/10 000 person years). Overall, current use of a double therapy combination containing either diuretics or angiotensin converting enzyme inhibitors or angiotensin receptor blockers with NSAIDs was not associated with an increased rate of acute kidney injury. In contrast, current use of a triple therapy combination was associated with an increased rate of acute kidney injury (rate ratio 1.31, 95% confidence interval 1.12 to 1.53). In secondary analyses, the highest risk was observed in the first 30 days of use (rate ratio 1.82, 1.35 to 2.46). Conclusions A triple therapy combination consisting of diuretics with angiotensin converting enzyme inhibitors or angiotensin receptor blockers and NSAIDs was associated with an increased risk of acute kidney injury. The risk was greatest at the start of treatment. Although antihypertensive drugs have cardiovascular benefits, vigilance may be warranted when they are used concurrently with NSAIDs.

[1]  C. McCulloch,et al.  Nonrecovery of kidney function and death after acute on chronic renal failure. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[2]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[3]  L. G. García Rodríguez,et al.  Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. , 1996, Archives of internal medicine.

[4]  K. Rothman,et al.  Using prescription claims data for drugs available over‐the‐counter (OTC) , 2007, Pharmacoepidemiology and drug safety.

[5]  S. Engel,et al.  Risk of acute renal failure in patients with Type 2 diabetes mellitus , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[6]  A. S. Appel,et al.  Acute Renal Failure , 1960, Advances in Experimental Medicine and Biology.

[7]  A K Mortagy,et al.  Risk factors and outcome of hospital-acquired acute renal failure (clinical epidemiologic study). , 1988, The Journal of the Egyptian Public Health Association.

[8]  Samy Suissa,et al.  Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages , 2007, Nature Clinical Practice Rheumatology.

[9]  Azeem Majeed,et al.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009 , 2010, Journal of the Royal Society of Medicine.

[10]  Sushrut S Waikar,et al.  Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[12]  S. Hernández-Díaz,et al.  Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. , 2001, The American journal of medicine.

[13]  L. G. García Rodríguez,et al.  Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.

[14]  M. Mancone,et al.  Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. , 2012, Journal of nephrology.

[15]  Tyler J. VanderWeele,et al.  Estimating measures of interaction on an additive scale for preventive exposures , 2011, European Journal of Epidemiology.

[16]  Amit X Garg,et al.  Validity of administrative database coding for kidney disease: a systematic review. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  J. Lafrance,et al.  Selective and non‐selective non‐steroidal anti‐inflammatory drugs and the risk of acute kidney injury , 2009, Pharmacoepidemiology and drug safety.

[18]  S. Hou,et al.  Hospital-acquired renal insufficiency. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  K. Loboz,et al.  Drug combinations and impaired renal function -- the 'triple whammy'. , 2005, British journal of clinical pharmacology.

[20]  S. Suissa.  Immeasurable time bias in observational studies of drug effects on mortality. , 2008, American journal of epidemiology.

[21]  J. Brophy,et al.  Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. , 2006, American journal of epidemiology.

[22]  B. Psaty,et al.  Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. , 2010, JAMA.

[23]  Giuseppe Remuzzi,et al.  Clinical practice. Nephropathy in patients with type 2 diabetes. , 2002, The New England journal of medicine.

[24]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[25]  Michael J. Miller,et al.  Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007. , 2009, Journal of the American Pharmacists Association : JAPhA.

[26]  Stephanie S. Taber,et al.  The epidemiology of drug-induced disorders: the kidney. , 2008, Expert opinion on drug safety.

[27]  C. Valdez,et al.  Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[28]  V. Adhiyaman,et al.  Nephrotoxicity in the Elderly Due to Co-Prescription of Angiotensin Converting Enzyme Inhibitors and Nonsteroidal Anti-Inflammatory Drugs , 2001, Journal of the Royal Society of Medicine.

[29]  C. McCulloch,et al.  Community-based incidence of acute renal failure. , 2007, Kidney international.

[30]  C. Huerta,et al.  Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  B. Stricker,et al.  Confounding by Contraindication in a Nationwide Cohort Study of Risk for Death in Patients Taking Ibopamine , 2001, Annals of Internal Medicine.

[32]  D. Angus,et al.  Patients are dying of acute renal failure. , 2002, Critical care medicine.

[33]  H. Allore,et al.  Antidepressant use and cognitive deficits in older men: addressing confounding by indications with different methods. , 2012, Annals of epidemiology.

[34]  L. Køber,et al.  Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes , 2007, Circulation.

[35]  Beverley Matthews,et al.  Estimating the financial cost of chronic kidney disease to the NHS in England , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  L. Smeeth,et al.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.

[37]  P. Rose,et al.  Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[38]  J. Thurman,et al.  Peeking into the black box: new biomarkers for acute kidney injury. , 2008, Kidney international.

[39]  C. McCulloch,et al.  Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. , 2009, Kidney international.

[40]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[41]  Jixian Wang,et al.  Opportunities for minimization of confounding in observational research , 2011, Pharmaceutical statistics.

[42]  Alessandro Filippi,et al.  Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients , 2009, Circulation.

[43]  Merlin C. Thomas,et al.  Diuretics, ACE inhibitors and NSAIDs — the triple whammy , 2000, The Medical journal of Australia.

[44]  G. Hasenfuss,et al.  The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects , 2006, European Journal of Clinical Pharmacology.

[45]  R. Greger.  Physiology of renal sodium transport. , 2000, The American journal of the medical sciences.

[46]  P. Jorens,et al.  Exposure of the elderly to potential nephrotoxic drug combinations in Belgium , 2008, Pharmacoepidemiology and drug safety.

[47]  Adrian Derungs,et al.  [Drug-induced acute kidney injury]. , 2015, Therapeutische Umschau. Revue therapeutique.

[48]  L. Price,et al.  Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[49]  S. Garella,et al.  Drug-induced renal disease. , 1993, Hospital practice.

[50]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[51]  Electronic publishing: now and tomorrow. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  R. Rapanà,et al.  Acute renal failure of medical type in an elderly population. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  Giuseppe Remuzzi,et al.  Nephropathy in Patients with Type 2 Diabetes , 2002 .

[54]  Toshiharu Fujita,et al.  Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database , 2008, Journal of epidemiology.

[55]  N. Breslow,et al.  Statistics in Epidemiology : The Case-Control Study , 2008 .